Global Information
회사소개 | 문의

요관암 : 파이프라인 리뷰

Ureter Cancer - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 04월 상품 코드 247802
페이지 정보 영문 154 Pages
가격
US $ 2,000 ₩ 2,242,400 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,484,800 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,727,200 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


요관암 : 파이프라인 리뷰 Ureter Cancer - Pipeline Review, H1 2018
발행일: 2018년 04월 페이지 정보 : 영문 154 Pages

한글목차

요관암의 증상은 요도로부터의 출혈 또는 혈뇨, 고름, 서혜부의 림프절 종대 등을 볼 수 있습니다. 위험인자로는 흡연이 있습니다. 치료는 수술, 화학요법, 방사선 요법을 시행합니다.

요관암 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

요관암 개요

치료제 개발

  • 파이프라인 제품;개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Altor BioScience Corp
  • Eisai Co Ltd
  • Exelixis Inc
  • GlaxoSmithKline Plc
  • MedImmune LLC
  • Merck & Co Inc

약제 개요

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSA 17.06.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H1 2018, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.

Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.

Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ureter Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ureter Cancer - Overview
    • Ureter Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Ureter Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ureter Cancer - Companies Involved in Therapeutics Development
    • Altor BioScience Corp
    • Eisai Co Ltd
    • Exelixis Inc
    • GlaxoSmithKline Plc
    • MedImmune LLC
    • Merck & Co Inc
  • Ureter Cancer - Drug Profiles
    • ALT-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target FOLR1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PSMA for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eribulin mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3326595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Mechanism Of Action
      • R&D Progress
    • PGV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ureter Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Ureter Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Ureter Cancer - Pipeline by Altor BioScience Corp, H1 2018
  • Ureter Cancer - Pipeline by Eisai Co Ltd, H1 2018
  • Ureter Cancer - Pipeline by Exelixis Inc, H1 2018
  • Ureter Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Ureter Cancer - Pipeline by MedImmune LLC, H1 2018
  • Ureter Cancer - Pipeline by Merck & Co Inc, H1 2018

List of Figures

  • Number of Products under Development for Ureter Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research